Founded in 1990 and headquartered in Toulouse, Teknimed specializes in the development, manufacture and distribution of biomaterials, including bone cements and bone substitutes used in orthopedic and spine surgery.
The transaction is part of a proposed restructuring of Teknimed’s share capital, which is currently majority owned by Essling Capital, and provides for the continued ownership stake of Carole Léonard, its CEO. It is intended to support the company’s growth, particularly internationally, and to further its growth strategy, including through external growth transactions.